Other dual GLP-1R/GCGR agonists are being actively studied to treat NAFLD, with Pemvidutide (ALT-801) emerging as a promising candidate for managing obesity and MASH [97]. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.